Domov › Burkittov limfom › Ohio
Klinične študije za Burkittov limfom v Ohio
17 študij za Burkittov limfom išče udeležence na lokacijah v Ohio.
Mesta v Ohio
Uradno besedilo študije (angleško)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- in še 3
Vključevanje udeležencevFaza 2
366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Case Western Reserve University, Cleveland
- Cleveland Clinic Foundation, Cleveland
- in še 2
Vključevanje udeležencevFaza 3
Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
Vključevanje udeležencevOpazovalna študija
Starost 0–38 · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- in še 2
Vključevanje udeležencevFaza 2
365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
Vključevanje udeležencevFaza 3
Starost 1 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07223021A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- in še 3
Vključevanje udeležencevFaza 2
Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- in še 4
Vključevanje udeležencevFaza 3
365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
Vključevanje udeležencevFaza 2
Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
Vključevanje udeležencevFaza 1/2
Starost 13–90 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06533579Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 1
Starost 2 in več · Vsi spoli · Posodobljeno 29. maj 2026 · NCT05418088Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Cleveland Clinic Foundation, Cleveland
Vključevanje udeležencevFaza 2
Starost 18–54 · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06918431Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
Vključevanje udeležencevFaza 1
Starost 1–39 · Vsi spoli · Posodobljeno 18. feb. 2026 · NCT06863259Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 13. feb. 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Cleveland Clinic, Cleveland
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 5. nov. 2025 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 15. nov. 2024 · NCT06034275Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.